Eli Lilly's Alzheimer's drug is rejected by EU regulators over brain swelling risk, despite U.S. approvalByBruce GilPublishedMarch 28, 2025
Cheaper Wegovy, 23andMe shutters, and RFK Jr. cuts FDA jobs: Pharma news roundupByBruce GilPublishedMarch 28, 2025
Wegovy sales took a hit this year. Novo's CEO blames off-brand competitionByBruce GilPublishedMarch 27, 2025
RFK Jr. plans to cut 3,500 jobs at the FDA, as staff is reportedly already struggling with workloadByBruce GilPublishedMarch 27, 2025
Eli Lilly's online health platform just expanded beyond weight loss to tackle Alzheimer’sByBruce GilPublishedMarch 27, 2025
The ad biz is bracing for slower growth this year — and the economy's to blameByBruce GilPublishedMarch 26, 2025
GLP-1s are driving returns on R&D investments for Big Pharma, report saysByBruce GilPublishedMarch 25, 2025
Netflix, YouTube, Disney and more: The 8 most-watched platforms in FebruaryByBruce GilPublishedMarch 25, 2025
Novo Nordisk's weight loss drug Wegovy is now cheaper for even more patientsByBruce GilPublishedMarch 24, 2025
8 key drug patents expiring soon — and what it means for the marketByBruce GilPublishedMarch 24, 2025
Johnson & Johnson is the latest pharma giant to court Trump with new investment plansByBruce GilPublishedMarch 21, 2025
Now playing Elon Musk urges Tesla staffers to 'hang onto your stock' even though it has fallen 50%PublishedMarch 21, 2025
